- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gilead Sciences Inc (GILD)
Track today's live Gilead (GILD) share price, performance and key data on this page with our current NASDAQ:GILD stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Gilead share price on the NASDAQ exchange. Use the dropdown to switch exchange for the GILD share price, head to our technical summary section, which provides analysis on Gilead share price buy/sell indicators using real-time data (or discuss the Gilead (GILD) stock price today with other investors in the Gilead NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GILD share price (ISIN: US3755581036) to enhance your trading decisions with our free investment tools and resources.
What Is the Gilead Sciences Inc Share Price Today?
The Gilead share price today is 138.36.
What Is the Stock Symbol for Gilead Sciences Inc
The stock symbol (or 'ticker') for Gilead Sciences Inc is "GILD."
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the NASDAQ stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:GILD share price (ISIN: US3755581036) to enhance your trading decisions with our free investment tools and resources.
What Is the Gilead Sciences Inc Share Price Today?
The Gilead share price today is 138.36.
What Is the Stock Symbol for Gilead Sciences Inc
The stock symbol (or 'ticker') for Gilead Sciences Inc is "GILD."
What Stock Exchange Does Gilead Sciences Inc Trade On?
Gilead Sciences Inc is listed and trades on the NASDAQ stock exchange.
Is Gilead Sciences Inc a Good Stock to Buy?
Determining whether Gilead (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
135.91
138.43
52 wk Range
108.46
157.29
GILD is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
135.91138.43
52 wk Range
108.46157.29
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.37%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(2.37%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GILD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
157.41
Upside
+13.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
12 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
22 Buy
7 Hold
0 Sell
Ratings:
29 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 157.41
(+13.77% Upside)
Gilead Sciences Inc SWOT Analysis
HIV Market Dynamics | Explore Gilead's strategies to maintain dominance in HIV therapeutics amid challenges like formulary exclusions and potential government funding cuts |
Oncology Ambitions | Discover how Gilead's expanding oncology portfolio, led by Trodelvy and Cell therapies, is poised to drive future growth and valuation |
Financial Health | Delve into Gilead's robust financial position, with a market cap of $140.17B and strong EBITDA, supporting its ambitious commercial initiatives |
Analyst Outlook | Learn about Gilead's price targets, ranging from $115 to $130, reflecting diverse views on the company's growth potential and market positioning |
Gilead Sciences Inc Earnings Call Summary for Q2/2026
- Gilead Q2 2026 revenue hit $7.8B, beating $7.4B forecast; adjusted loss of $6.75/share narrower than expected $7.31 loss.
- Base business sales surged 10% YoY to $7.6B, strongest Q2 growth in three years; HIV sales up 12% to $5.7B with raised guidance to 9-10%.
- Yeztugo PrEP drug surpassed $1B annual run rate with $232M quarterly sales, more than doubling YoY; Trodelvy oncology sales rose 26% to $457M.
- Company raised full-year base business sales outlook to $29.8-30.1B, up 6-7%; expects FDA decisions on BIC/LEN by Aug 27, anito-cel by Dec 23.
- Reported $11.2B in IPR&D charges from Arcellx, Tubulis, Ouro acquisitions; stock slipped 0.84% after-hours despite beating estimates.
Last Updated: 04/08/2026, 22:58
Read Full TranscriptEarnings
Latest Release
04/08/2026
EPS / Forecast
-6.75 / -7.31
Revenue / Forecast
7.8B / 7.4B
Compare GILD to Peers and Sector
Metrics to compare | GILD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGILDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −52.9x | −4.1x | −0.4x | |
PEG Ratio | 0.35 | 0.02 | 0.00 | |
Price/Book | 14.5x | 1.2x | 2.6x | |
Price / LTM Sales | 5.6x | 1.0x | 3.1x | |
Upside (Analyst Target) | 15.8% | 17.8% | 47.8% | |
Fair Value Upside | Unlock | −0.7% | 6.2% | Unlock |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Gilead (NASDAQ: GILD) Share Price Today?
The Gilead stock price today is 138.36 USD.
What Stock Exchange Does Gilead (GILD) Trade On?
Gilead is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Gilead?
The stock symbol (also called a 'ticker') for Gilead is "GILD."
Does Gilead Pay Dividends? What’s The Current GILD Dividend Yield?
Yes, GILD Pays Dividends to its Shareholders. The current Gilead dividend yield is 2.37%.
What Is the Current Gilead Market Capitalisation?
As of today, Gilead (NASDAQ: GILD) market cap is 171.29B USD.
What Is Gilead's (GILD) Earnings Per Share (TTM)?
The Gilead EPS is currently -2.62 (Trailing Twelve Months).
When Is the Next Gilead Earnings Date?
Gilead's next earnings report will be released on 22/10/2026.
Is GILD a Buy or Sell From a Technical Analyst Perspective?
Based on today's Gilead moving averages and other technical indicators, the daily buy/sell signal for GILD stock is Strong Buy.
How Many Times Has Gilead Stock Split?
Gilead has split 5 times. (See the GILD stock split history page for full effective split date and price information.)
How Many Employees Does Gilead Have?
Gilead has 17000 employees, based on their latest Companies House report.
What is the current trading status of Gilead (NASDAQ: GILD)?
As of 15/08/2026, Gilead (GILD) is trading at a share price of 138.36 USD, with a previous close of 138.14 USD. The stock has fluctuated within a day range of 135.91 USD to 138.43 USD, while its 52-week range spans from 108.46 USD to 157.29 USD.
What Is Gilead (GILD) Price Target According to Analysts?
The average 12-month price target for Gilead is 157.41 USD, with a high estimate of 180 USD and a low estimate of 123 USD. 22 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +13.77% Upside potential.
What Is the GILD Premarket Price?
GILD's last pre-market stock price is 136.20 USD. The pre-market share volume is 6,430.00, and the stock has decreased by -1.94, or -1.40%.
What Is the GILD After Hours Price?
GILD's last after hours stock price is 138.00 USD, the stock has decreased by -0.36, or -0.26%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.